Vanguard Group Inc Cyma Bay Therapeutics, Inc. Transaction History

Vanguard Group Inc

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$12.63 - $24.47 $7.05 Million - $13.7 Million	558,562 Added 9.72%	6,306,149 $149 Million
Q3 2023 Nov 14, 2023	BUY	$10.86 - $17.62 $6.5 Million - $10.5 Million	598,707 Added 11.63%	5,747,587 $85.7 Million
Q2 2023 Aug 14, 2023	BUY	$7.47 - $10.95 $5.22 Million - $7.66 Million	699,272 Added 15.72%	5,148,880 $56.4 Million
Q1 2023 May 15, 2023	BUY	$5.88 - $9.59 $4.55 Million - $7.43 Million	774,310 Added 21.07%	4,449,608 $38.8 Million
Q4 2022 Feb 10, 2023	BUY	$3.22 - $6.27 $32,959 - $64,179	10,236 Added 0.28%	3,675,298 $23 Million
Q3 2022 Nov 14, 2022	BUY	$2.77 - $4.25 $299,215 - $459,085	108,020 Added 3.04%	3,665,062 $12.8 Million
Q2 2022 Aug 12, 2022	SELL	$1.72 - $3.39 $490,774 - $967,282	-285,334 Reduced 7.43%	3,557,042 $10.5 Million
Q1 2022 May 13, 2022	BUY	$2.77 - $3.64 $149,355 - $196,265	53,919 Added 1.42%	3,842,376 $12 Million
Q4 2021 Feb 14, 2022	BUY	$3.23 - $4.6 $1.43 Million - $2.04 Million	443,149 Added 13.25%	3,788,457 $12.8 Million
Q3 2021 Nov 12, 2021	BUY	$3.47 - $4.42 $64,285 - $81,884	18,526 Added 0.56%	3,345,308 $12.2 Million
Q2 2021 Aug 13, 2021	BUY	$3.94 - $4.92 $13.1 Million - $16.4 Million	3,326,782 New	3,326,782 $14.5 Million

1.82M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

Stay updated on Vanguard Group Inc with notifications on news.